rabbit anti-prox-1 polyclonal antibody  (Merck & Co)

Journal: Cancers

Article Title: CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1

doi: 10.3390/cancers13194859

Figure Lengend Snippet: CD147 regulates LECs lymphangiogenic markers at transcriptional and translational levels. ( a ) qRT-PCR of FLT4 , PROX1 , LYVE1 , and PDPN expression in LECs treated or not with rhCD147, using PPIA as a reference. Columns indicate the means of three independent experiments carried out in triplicate; bars indicate SD; * p < 0.05, ** p < 0.005, *** p < 0.0001. ( b ) Western blot analyses of VEGFR-3, PROX-1, LYVE-1, Podoplanin, and CD147 expression in total lysates of LECs treated or not with rhCD147. ( c ) Three independent Western blots were quantified for densitometry band analyses. Equal loading of proteins was assessed by probing for β-actin. Bars, SD; * p < 0.05, ** p <0.005, *** p < 0.0001. ( d ) Representative confocal images of PROX-1, LYVE-1 and Podoplanin immunofluorescent staining on LECs treated or not with rhCD147 (63X magnification). Scale bar: 30 µm. ( e ) ChIP-qPCR was performed on LECs treated or not with rhCD147, with antibody against PROX-1 total and control IgG. Columns indicate means of two independent experiments; and bars, SD; ns, non significant, * p < 0.05, ** p < 0.005, *** p < 0.0001.

Article Snippet: Then, 20 µg of lysate in 4× Laemmli per lane were resolved by reducing 10% SDS-PAGE followed by Western blot analyses with either Rabbit anti-LYVE-1 polyclonal antibody (#ab14917, Abcam, Cambridge, UK), Rabbit anti-VEGFR-3 polyclonal antibody (#102-PA22AG, ReliaTech), Rabbit anti-PROX-1 polyclonal antibody (#07-537, Merck), Mouse anti-Podoplanin monoclonal antibody (#ab10288, Abcam, Cambridge, UK) or Mouse monoclonal anti-β-actin antibody (#A2228, Merck) for loading control.

Techniques: Quantitative RT-PCR, Expressing, Western Blot, Staining

Journal: Cancers

Article Title: CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1

doi: 10.3390/cancers13194859

Figure Lengend Snippet: CD147 regulates LECs lymphangiogenic markers through PROX-1 transcription factor. LECs were transfected with scrambled or PROX-1 siRNA and treated or not with rhCD147. ( a ) qRT-PCR of PROX1 , PDPN , and LYVE1 expression using PPIA as a reference. Columns indicate means of three independent experiments carried out in triplicate; bars indicate SD; * p < 0.05, *** p < 0.0001 for siRNA-PROX-1 vs. siRNA-scrambled. ns, nonsignificant, # p < 0.05, ### p < 0.0001 for treated vs. untreated cells. ( b ) Representative confocal images of immunofluorescence staining for PROX-1, Podoplanin and LYVE-1 (63× magnification).

Article Snippet: Then, 20 µg of lysate in 4× Laemmli per lane were resolved by reducing 10% SDS-PAGE followed by Western blot analyses with either Rabbit anti-LYVE-1 polyclonal antibody (#ab14917, Abcam, Cambridge, UK), Rabbit anti-VEGFR-3 polyclonal antibody (#102-PA22AG, ReliaTech), Rabbit anti-PROX-1 polyclonal antibody (#07-537, Merck), Mouse anti-Podoplanin monoclonal antibody (#ab10288, Abcam, Cambridge, UK) or Mouse monoclonal anti-β-actin antibody (#A2228, Merck) for loading control.

Techniques: Transfection, Quantitative RT-PCR, Expressing, Immunofluorescence, Staining